Loading clinical trials...
Loading clinical trials...
Study of The Therapeutic Benefits of Nigella Sativa in Children With Beta Thalassemia Major
Evaluate the therapeutic effects health benefits, and immunological effect of Nigella sativa in children with beta thalassemia major.
Study will be carried on children patients with β- thalassemia major attending The Hematology Unit of Pediatric Department at Tanta University Hospital. patients are divided into 2 groups: patients in the control group, patients in the treatment group that will receive nigella sativa powder for 3 consecutive months. Then Evaluate the therapeutic effects health benefits, and immunological effect of Nigella sativa in children with beta thalassemia major. Evaluate the extent of clinical improvement, reductions in serum iron and ferritin, antioxidant status, treatment of the causes of hemolysis and other therapeutic benefits of Nigella sativa in those patient.
Age
3 - 18 years
Sex
ALL
Healthy Volunteers
No
Faculty of Medicine- Tanta University
Tanta, Gharbia Governorate, Egypt
Start Date
June 1, 2016
Primary Completion Date
June 1, 2017
Completion Date
June 1, 2017
Last Updated
April 26, 2017
80
ESTIMATED participants
nigella sativ
DRUG
Lead Sponsor
Tanta University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions